Vaxcyte, a clinical-stage vaccine company, re-engineers complex vaccines using advanced chemistry and synthetic techniques including cell-free protein synthesis.
Vaxcyte is a clinical-stage vaccine company that re-engineers vaccine manufacturing with cell-free protein synthesis and develops pneumococcal conjugate vaccine candidates designed for broad serotype coverage. The company employs advanced chemistry and synthetic techniques to produce difficult-to-make proteins.
Its vaccine candidates VAX-31 and VAX-24 are being studied for the prevention of invasive pneumococcal disease, which is especially serious in infants, young children, older adults, and people with immune deficiencies or certain chronic health conditions. VAX-31 was designed to cover, in a single vaccine, more than 95% of invasive pneumococcal disease circulating in United States adults aged 50 and older.
